Microsatellite variation in Spanish Alano dogs

We have studied a sample of 35 spanish alano dogs in order to estimate the level of genetic variability that can be detected by using microsatellites and the efficiency of these genetic markers as tools for parentage testing in this canine population. We have used 4 microsatellites previously described in the literature. All of them were polymorphic, with an average number of 5 alleles/ locus and an average gene diversity (H) of 0,70 ± 0,06, similar to the figures reported in others breeds. Two of the microsatellites showed disa-greement with Hardy-Weinberg proportions, due to a deficit of heterozygotes. We have found in one of the microsatellites alleles that could be breed specific, as they have not been detected in other spanish breeds. The combined exclusion probability detected is higher than 90 percent, suggesting the possibility of using efficiently microsatellites in parentage testing in the spanish alano population.En una muestra de 35 alanos españoles se investigó la utilidad de los microsatélites para detectar variabilidad genética y para el control de paternidad. Los 4 microsatélites utilizados, descritos ya en la bibliografía, resultaron polimórficos, con un número medio de 5 alelos/ locus y una heterocigosis media (H), de 0,70 ± 0,06, similar a la de otras razas caninas. Se ha detectado una desviación del equilibrio Hardy-Weinberg para dos microsatélites debida a un déficit de heterocigotos. En un microsatélite se han detectado alelos inexistentes en otras razas españolas, por lo que podrían ser específicos de raza. La probabilidad acumulada de exclusión de paternidad es superior al 90 p.100, por lo que podrían ser eficaces para estas pruebas en alanos

Antígenos leucocitarios como genes candidatos para mejorar la respuesta inmune en cerdos

Leukocyte antigens (CD) have functions related to immune response and are of interest as classical candidate genes for health. Polymorphisms (e.g. SNPs) in these genes may be associated with variation in the immune response and consequently in disease response. This approach is being taken in search of susceptibility genes for swine disease. In addition, these genes may vary between populations, especially where specific adaptation to pathogens has occurred, and are of potential interest in characterising pig biodiversity.Los antígenos leucocitarios (CD) tienen funciones relacionadas con la respuesta inmune y son de interés con genes candidatos clásicos para la salud. Los Polimorfismos (ej. SNPs) en estos genes pueden estar asociados con variaciones en la respuesta inmune y consecuentemente con la respuesta a la enfermedad. Este ensayo se está desarrollando en la búsqueda de susceptibilidades genéticas a enfermedades porcinas. Adicionalmente, estos genes pueden variar entre poblaciones, especialmente en la que han ocurrido adaptaciones a patógenos, y suponen un interés potencial para la caracterización de la biodiversidad porcina

Síndrome de Sweet. Presentación de Caso

El síndrome de Sweet o dermatosis neutrofílica febril aguda es un proceso caracterizado por fiebre, placas eritematosas dolorosas, neutrofilia e infiltrado dérmico constituido por neutrófilos con edema papilar sin vasculitis. Su asociación con la enfermedad inflamatoria intestinal es inusual. Debido a la rareza de esta patología dermatológica presentamos un nuevo caso de síndrome de Sweet asociado a colitis ulcerosa, cuyo objetivo es describir las características clínicas de la paciente con esta entidad, teniendo en cuenta la infrecuencia de esta enfermedad en Mayabeque y en Cuba, lo que constituye un ejemplo para futuros diagnósticos en las áreas de salud. El diagnóstico histológico corroboró la sospecha clínica y la paciente fue tratada con corticoesteroides sistémicos, evolucionando satisfactoriamente

Síndrome de Sweet. Presentación de Caso

El síndrome de Sweet o dermatosis neutrofílica febril aguda es un proceso caracterizado por fiebre, placas eritematosas dolorosas, neutrofilia e infiltrado dérmico constituido por neutrófilos con edema papilar sin vasculitis. Su asociación con la enfermedad inflamatoria intestinal es inusual. Debido a la rareza de esta patología dermatológica presentamos un nuevo caso de síndrome de Sweet asociado a colitis ulcerosa, cuyo objetivo es describir las características clínicas de la paciente con esta entidad, teniendo en cuenta la infrecuencia de esta enfermedad en Mayabeque y en Cuba, lo que constituye un ejemplo para futuros diagnósticos en las áreas de salud. El diagnóstico histológico corroboró la sospecha clínica y la paciente fue tratada con corticoesteroides sistémicos, evolucionando satisfactoriamente

Effect of simulated brushing on surface roughness and wear of bis-acryl-based materials submitted to different polishing protocols

Provisional materials must have enough strength to withstand masticatory loads without suffering deformation or fracture, and their surfaces must have good finishing and polishing characteristics to reduce biofilm accumulation. Thus, the purpose of this

Patients with Axial Spondyloarthritis Show an Altered Flexion/Relaxation Phenomenon

Axial spondyloarthritis (axSpA) is a chronic rheumatic disease characterized by the presence of inflammatory back pain. In patients with chronic low back pain, the lumbar flexion relaxation phenomenon measured by surface electromyography (sEMG) differs from that in healthy individuals. However, sEMG activity in axSpA patients has not been studied. The purpose of this study was to analyze the flexion relaxation phenomenon in axSpA patients. A study evaluating 39 axSpA patients and 35 healthy controls was conducted. sEMG activity at the erector spinae muscles was measured during lumbar full flexion movements. sEMG activity was compared between axSpA patients and the controls, as well as between active (BASDAI ≥ 4) and non-active (BASDAI 0.8 for 1/FRR) and criterion validity. ROC analysis showed good discriminant validity for axSpA patients (AUC = 0.835) vs. the control group using 1/FRR. An abnormal flexion/relaxation phenomenon exists in axSpA patients compared with controls. sEMG could be an additional objective tool in the evaluation of patient function and disease activity status

EL TRASTORNO LÍMITE DE PERSONALIDAD: LA FILOSOFÍA DIALÉCTICA COMO BASE DE LA INTERACCIÓN ENFERMERO PACIENTE

Borderline personality disorder was defined in the nineteenth century as the boundary between psychosis and neurosis. It has three major clinical components: a shaky sense of self, a high level of impulsivity and high affective instability. Due in part to the lack of knowledge of the underlying dynamics, working with patients with BPD is often difficult for nursing staff. The present study aims to propose guidelines that encourage interactive psychotherapy in the care of patients with this disorder. To this objective we conducted a bibliographic search in Nursing and other health science databases (Cochrane, Tripdatabase, Medline, CINAHL and care), using Mesh descriptors: "Borderline personality disorder" AND "therapy" and “Borderline Personality" AND "nursing cares", indexed from 01/01/2000, finally selecting a total of 17 studies for their relevance and relationship to the subject under study. Based on the results, we suggest the use of dialectical philosophy, the basis of dialectical-behavioral therapy developed by Marsha Linehan, a tool that will lead to a better nurse-patient relationship, greater adherence to treatment and greater efficiency in managing time and resources. El trastorno límite de personalidad fue definido ya en el siglo XIX, como límite entre la psicosis y la neurosis. Presenta tres componentes clínicos principales: un inestable sentido del yo, un alto nivel de impulsividad y una elevada inestabilidad afectiva . Debido en parte, a la falta de conocimiento de la dinámica subyacente, el trabajo con pacientes con TLP resulta a menudo difícil para el personal de Enfermería.El presente estudio tiene por objeto proponer orientaciones psicoterapéuticas que favorezcan la interacción en el cuidado de pacientes con este trastorno. Para este fin se lleva a cabo una búsqueda bibliográfica en las principales basos de datos de Enfermería y del resto de ciencias de la salud (Cochrane, Tripdatabase, Medline, CINAHL y CUIDEN), empleando los descriptores Mesh: “Borderline personality disorder” AND “therapy” y“Borderline personality” AND “nursing cares”, indexados a partir del 01/01/2000, seleccionando finalmente un total de 17 estudios por su relevancia y relación con el tema.Atendiendo a los resultados obtenidos, proponemos el empleo de la filosofía dialéctica, base de la terapia dialéctico-comportamental desarrollada por Marsha Linehan, como herramienta que va a conducir a una mejor relación enfermero-paciente, una mayor adherencia al tratamiento y una mayor eficiencia en la gestión de tiempo y recursos

Contribución al conocimiento de la flora de Andalucía: citas novedosas e interesantes de la provincia de Almería

Contribution to the knowledge about Andalusian flora: new and interesting cites of the Almería province.Palabras clave. Corología, Isla de Alborán, sureste ibérico, xenófitas.Key words. Corology, Alborán Island, South-Eastern Iberian Peninsula, xenophytes

EP05.02-003 Durvalumab after Chemoradiotherapy (CRT) in Unresectable Stage III NSCLC. Comparative Study of Two Cohorts in the Real-World Setting

[EN] Introduction: Durvalumab is the new standard of care for unresectable locally advanced NSCLC, with PD-L1 _1% and who did not have progression after CRT treatment in the European Union. Our study compares the effectiveness and the frequency of radiation pneumonitis in patients treated with concurrent CRT with or without durvalumab consolidation during the same period in real clinical practice. Methods: A single-center retrospective study. 71 treated patients with unresectable stage III NSCLC were included between March 2018 and December 2021, 37 with CRT followed by durvalumab and 34 with CRT alone. Real-world progression-free survival (rwPFS) and real-world overall survival (rwOS) were calculated since the date of the end CRT. Propensity score matching (PSM) 1:1 was used to account for differences in baseline characteristics. Results: Median age was 67 years (range 46-82). 25.4% of the patients were _75 years old. 78.9% were men and 53.5% former smokers. 54.9% had squamous histology and 28%, 51% and 21% stage IIIA, IIIB and IIIC disease, respectively. The most used scheme was carboplatinpaclitaxel (43.7%), receiving induction chemotherapy in up to 54.9% of patients. 73.2% received between 60-66 Gy doses of radiotherapy. Median time from end of CRT to onset durvalumab was 44 days (range 13-120) with a median of 14 infusions (range 6-27). Of the 34 patients without durvalumab treatment, the expression PD-L1 <1% (58.8%) was the most frequent cause for rejecting consolidation therapy. After PSM analysis, patients distributions were well balanced. With a median follow-up of 19.7 months (range 1.4-36.6); median rw-PFS was 9.3 months (95% CI, 5-13.5) without durvalumab and 17 months (95% CI, 11-22.9) with durvalumab (p¼0.013). Median rw-OS was 19.3 months (95% CI, 3.8-34.8) without durvalumab and 29.9 months (95% CI, 23.3-36.6) with durvalumab (p¼0.241) with a rw-OS% at 6, 18 and 24 months of 90%, 62% and 49% vs 100%, 86% and 74%, respectively. The rate of radiation pneumonitis was more frequent with durvalumab consolidation (56.8% against 44.1%), (p¼0.346), especially within 3 months after CRT. G3 pneumonitis was only observed in the consolidation therapy. Conclusions: Our results demonstrate the effectiveness of durvalumab consolidation after CRT in real-world patients with unresectable stage III NSCLC. Further sample and longer follow-up are required to obtain more accurate results. Active surveillance and appropriate management for radiation pneumonitis are needed, in especially in candidates for consolidation treatmentS

EP05.02-002 Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?

[EN] Introduction: Durvalumab received EMA approval as consolidation therapy (CT) for unresectable stage III NSCLC with PD-L1 _1% and who did not have progression after CRT. Our objective was to analyze in real clinical practice the effectiveness of durvalumab and explore the clinical factors that may be associated with the benefit from CT. Methods: Retrospective study was made at Hospital of Leon (Spain), including 37 patients with locally advanced NSCLC treated with durvalumab after CRT treatment between March 2018 and october 2021 (40.5% patients were included in the durvalumab early access program). The neutrophil-to-lymphocyte ratio (NLR) could identified after CRT as a factor that may be benefit from durvalumab. Results: Median age was 67 years (range 46-82 years). 40.5% of patients were _70 years old. 78.4% were male and 51.4% smokers. 54% had non-squamous histology. PD-L1 expression was <1% in 5% and not available in 8% patients. 2.7% ROS1 rearrangements, 5.4% KRAS mutations and not available in 43.2% patients. Stage IIIA, IIIB, IIIC disease were 24.3%, 54.1% and 21.6%, respectively. Median time from end of CRT to onset durvalumab was 44 days (range 13-120 days). Overall median CT duration was 214.8 days (range 69-399 days) with a median of 14 infusions (range 6-27 infusions). With a median follow up of 19.7 months (range 1.4-34.9 months); 67.6% had stopped CT: 37.8% due to completing treatment, 16.2% disease progression, 10.8% adverse event and 2.7% due to COVID19 infection. Median real-world progressionfree survival (rwPFS) was 17 months (95% CI, 11-23). Median realworld overall survival (rwOS) was 29.9 months (95% CI, 23.3-36.6). % rwOS at 6, 18 and 24 months were 100%, 86.9% and 74.5%, respectively. For patients with post-CRT NLR not exceeding the cohort median value of 6, receipt of durvalumab was associated with an improvement in rwOS (median not reached vs 25.7 months; p¼0.025). 56.8% patients had any grade of radiation pneumonitis (median time from CRT start: 119 days [range 36-241 days]). Of these, 19% patients developed worsening of radiation pneumonitis with durvalumab. 54,1% developed immune-mediated toxicity, mostly G1-2 (85.1%). Conclusions: Our results demonstrate the effectiveness of durvalumab consolidation in this patients population in a real-life setting. We identified low NLR after CRT as a potentially predictive factor for the benefit of CT in locally advanced NSCLC.S